Roche plans to release the system in the US to run tests including vitamin D and steroid assays under CLIA before it possibly receives US Food and Drug Administration clearance.

Abbott reported $9.34 billion in diagnostics revenues in 2024, down 7 percent on a reported basis from $9.99 billion in 2023 and down 4 percent on an organic basis. Excluding COVID-19 testing-related ...

The partners plan to expand testing for early detection of childhood leukemias and lymphomas, bolster local testing capacity, and conduct a research study.

The Amsterdam-based biotech firm said that its melt curve analysis-based test is used as a first-tier genetic screening tool to aid the diagnosis of SMA.